Technology | Nuclear Imaging | July 16, 2018

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

New features bring high-level clinical capabilities to PET imaging in oncology and neurology

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

July 16, 2018 — At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia, Siemens Healthineers announced U.S. Food and Drug Administration (FDA) clearance of syngo.via VB30 for Molecular Imaging (MI). The latest version of the company’s intelligent imaging software, syngo.via VB30 for MI has new features designed to bring advanced clinical capabilities to positron emission tomography/computed tomography (PET/CT) imaging in oncology and neurology.

syngo.via VB30 for MI automatically calculates a patient’s Deauville score – an internationally recognized scoring system used by oncologists in the initial staging and evaluation of therapeutic response for patients with Hodgkin lymphoma and most types of non-Hodgkin lymphoma. By avoiding the laborious, time-consuming task of manual Deauville score determination, clinicians can save time and increase efficiency.

Also, syngo.via VB30 for MI offers a unique platform for viewing and interpreting parametric PET images. Using dedicated layouts that permit simultaneous visualization of the summed Standard Uptake Values (SUV), the metabolic rate of glucose (MRFDG), and distribution volume images, readers can easily quantify the FDG uptake of these parametric indices.

Additionally, the new platform’s PET/CT and single photon emission computed tomography (SPECT)/CT hybrid VRT (volume-rendering technique) feature enables 3-D visualization of the disease state in a single image. This feature permits user-friendly interpretation of the cancer relative to anatomical landmarks.

Finally, syngo.via VB30 for MI offers improvements for the quantitative analysis of various neurological conditions via either self-created or widely used databases for various disease states. The assessment of striatal activity in the evaluation of Parkinson’s disease, hypometabolic seizure foci in the evaluation of epilepsy, and amyloid plaque burden in the evaluation of dementia can be conducted quantitatively. This ability provides more information to the reading physician to help increase diagnostic confidence.

For more information: www.usa.healthcare.siemens.com

Related Content

This is Figure 2 from the article in Radiology: Acute encephalopathy. A 60 year-old-man without history of seizures presenting with convulsion. (A-B) Multifocal areas of FLAIR hyperintensity in the right cerebellum (arrows in A), left anterior cingular cortex and superior frontal gyrus (arrows in B). (C-D) Restricted diffusion in the left anterior cingulate cortex, superior frontal and middle temporal gyrus (arrows in D) and right cerebellum (arrows in E), consistent with cerebellar diaschisis. F)  #COVID19

This is Figure 2 from the article in Radiology: Acute encephalopathy. A 60 year-old-man without history of seizures presenting with convulsion. (A-B) Multifocal areas of FLAIR hyperintensity in the right cerebellum (arrows in A), left anterior cingular cortex and superior frontal gyrus (arrows in B). (C-D) Restricted diffusion in the left anterior cingulate cortex, superior frontal and middle temporal gyrus (arrows in D) and right cerebellum (arrows in E), consistent with cerebellar diaschisis. F) No hemosiderin deposits in gradient echo sequences.

Feature | Coronavirus (COVID-19) | July 06, 2020 | Dave Fornell, Editor
Four recent radiology studies, from New York, Italy, Iran and China, show how...
Nuclear Cardiology Optimistic About Return to Pre-COVID-19 Exam Levels. An American Society of Nuclear Cardiology (ASNC) member survey are confident nuclear cardiology volumes will return to pre-pandemic levels. #COVID19 #SARScov2
News | Nuclear Imaging | June 01, 2020
June 1, 2020 — While acknowledging the challenges their specialty is facing, more than two-thirds of respondents to a
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function.

Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function. Image courtesy of YaleNews.

News | PET Imaging | May 14, 2020
May 14, 2020 — New imaging technology allows scientists to see the widespread loss of brain synapses in early stages
Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 sc

Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 scan (arrow in C), later verified on pathology as true malignant lesion. Images created by J. Kuten et al., Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

News | Prostate Cancer | May 12, 2020
May 12, 2020 — The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting mali
The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and is now the SNMMI 2020 Annual Meeting — Virtual Edition
News | Coronavirus (COVID-19) | April 30, 2020
April 30, 2020 — The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and
 Siemens Healthineers has received clearance from the Food and Drug Administration (FDA) for its AIDAN artificial intelligence technologies on the Biograph family of positron emission tomography/computed tomography (PET/CT) systems

 Siemens Healthineers received clearance from the FDA for its AIDAN artificial intelligence technologies on the Biograph family of positron emission tomography/computed tomography (PET/CT) systems.

News | Artificial Intelligence | April 22, 2020
April 22, 2020 — Siemens Healthineers has received